Arizona Tribune - President Trump Fixing DEA Marijuana Policy: Defies Logic, Law, and Science, Says MMJ International Holdings

WASHINGTON, D.C. / ACCESS Newswire / December 3, 2025 / MMJ International Holdings, a pharmaceutical developer of a fully federally compliant, natural cannabinoid pharmaceutical for Huntington's Disease and Multiple Sclerosis, today released a sharply critical analysis of the Drug Enforcement Administration's marijuana research policies-calling them "mathematically impossible, legally contradictory, and scientifically indefensible."

For seven years, MMJ has been trapped in a bureaucratic paradox that prevents the company from advancing its FDA-authorized clinical program, despite already having:

• FDA Orphan Drug Designation

• FDA IND programs prepared for Phase 2/3 trials

• Fully manufactured GMP softgel capsules

• Completed stability data

• A DEA Schedule I import authorization

The barrier is not science or safety-but DEA procedure.

A Regulatory Paradox With No Legal Route Forward

To obtain a DEA bulk manufacturing registration for pharmaceutical cannabis, the agency requires applicants to first present a bona fide supply contract with another federally licensed cannabis manufacturer.

But federal law classifies cannabis as a Schedule I drug, making any negotiation, drafting, or agreement involving future cannabis supply a federal trafficking conspiracy.

Meaning:

• It is illegal to negotiate the contract DEA demands, and

• It is impossible to obtain the license without it.

MMJ International Holdings CEO Duane Boise described the situation plainly:

"This is a regulatory equation with no solution.
To follow the rule is to commit a felony, and to follow the law is to violate the rule.
DEA has created a system where compliance itself is illegal."

Meanwhile, Ultra-Potent THC Products Flourish in Plain Sight

While federally compliant pharmaceutical developers are blocked, state dispensaries nationwide openly sell high-potency THC concentrates, many reaching high levels of THC. These products:

• Remain federally illegal under the Controlled Substances Act

• Are linked by peer-reviewed research to psychosis, schizophrenia, and neurological destabilization

• Are widely accessible to young adults

Yet MMJ-operating entirely under federal authority-still cannot secure approval for:

• Consistent, stabilized pharmaceutical softgel capsules

• Produced under GMP standards

• Using natural full-spectrum cannabis extracts

• Intended exclusively for FDA-supervised human clinical trials

Boise added:

"If the goal is to reduce psychosis, violence, and public health harm, the priority should be regulating ultra-potent THC-not blocking standardized pharmaceutical capsules for Huntington's patients."

A System Officially Declared Unconstitutional

In 2025, the U.S. Department of Justice formally acknowledged that the DEA's Administrative Law Judge (ALJ) system-the tribunal required to adjudicate MMJ's case-was "unconstitutional from the start."

As a result:

• MMJ never received a lawful evidentiary hearing

• The company's 2018 application remains in limbo

• There is no functional mechanism to resolve the case without decisive administrative action

Boise characterized the situation as:

"Seven years of delay, despite full compliance, fully manufactured medicine, and FDA readiness.
This is not regulation-it is regulatory entropy."

The Human Cost Behind the Bureaucracy

The satire underscores a deadly serious problem:

• Huntington's Disease patients experience chorea-violent involuntary movements that destroy independence and quality of life

• MMJ's treatment has FDA Orphan Drug Designation

• The medicine is manufactured and ready

• The only barrier is one agency's procedural loop

Boise stressed:

"Every day of DEA delay is another day patients go without hope.
We built real medicine-standardized, federally legal medicine-yet we are blocked while dangerous products flourish unchecked."

MMJ Calls for Immediate Federal Action

MMJ International Holdings urges the federal government and DEA Administrator Terrance Cole to:

1. Resolve MMJ's application immediately under the Administrative Procedure Act

2. End the Catch-22 that makes compliance legally impossible

3. Prioritize pharmaceutical-grade cannabinoid medicine over unregulated high-potency THC

4. Align federal policy with science, public health, and international treaty obligations

Boise concluded:

"The universe is complicated-federal cannabis policy doesn't have to be.
Medicine should not be illegal while illegality is treated as medicine."

About MMJ International Holdings

MMJ International Holdings is a U.S.-based pharmaceutical company developing FDA-regulated, natural cannabinoid medicines. MMJ's subsidiaries-MMJ BioPharma Labs and MMJ BioPharma Cultivation-hold federal designations, IND programs, and DEA licensure for pharmaceutical research targeting Huntington's Disease and Multiple Sclerosis.

MMJ is represented by attorney Megan Sheehan.

CONTACT:
Madison Hisey
[email protected]
203-231-8583

SOURCE: MMJ International Holdings

View the original press release on ACCESS Newswire

M.O.Allen--AT